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OBJECTIVE— There is a recognized association among depression, diabetes, and cardiovas-
cular disease. The aim of this study was to examine in a sample representative of the general
population whether depression, anxiety, and psychological distress are associated with meta-
bolic syndrome and its components.
RESEARCHDESIGNANDMETHODS— Three cross-sectional surveys including clin-
ical health measures were completed in rural regions of Australia during 2004–2006. A stratified
random sample (n  1,690, response rate 48%) of men and women aged 25–84 years was
selected from the electoral roll. Metabolic syndrome was defined by the Third Report of the
National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults, Adult Treatment Panel III (NCEP ATP III), and International
Diabetes Federation (IDF) criteria. Anxiety and depression were assessed by the Hospital Anxiety
and Depression Scale and psychological distress by the Kessler 10 measure.
RESULTS— Metabolic syndrome was associated with depression but not psychological dis-
tress or anxiety. Participants with the metabolic syndrome had higher scores for depression (n
409, mean score 3.41, 95% CI 3.12–3.70) than individuals without the metabolic syndrome
(n 936, mean 2.95, 95% CI 2.76–3.13). This association was also present in 338 participants
with the metabolic syndrome and without diabetes (mean score 3.37, 95% CI 3.06–3.68). Large
waist circumference and low HDL cholesterol showed significant and independent associations
with depression.
CONCLUSIONS— Our results show an association between metabolic syndrome and de-
pression in a heterogeneous sample. The presence of depression in individuals with the meta-
bolic syndrome has implications for clinical management.
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R ecent definitions of metabolic syn-drome (1,2) specify the followingquantitative criteria: large waist cir-
cumference, high blood pressure, dyslip-
idemia (high triglycerides and low HDL
cholesterol), and fasting hyperglycemia
with underlying insulin resistance as the
likely mechanism. The combination of
these components is a strong predictor of
cardiovascular disease and type 2 diabe-
tes. Understanding the mechanisms in-
volved and factors associated with the
metabolic syndrome is of great interest
given the pandemic of obesity and in-
creasing prevalence of the metabolic syn-
drome (32% in the U.S. adult population
in 1999–2000 [3] using the Third Report
of the National Cholesterol Education
Program Expert Panel on Detection, Eval-
uation, and Treatment of High Blood
Cholesterol in Adults, Adult Treatment
Panel III [NCEP ATP III] [1], criteria and
28% in our region [4]).
There is an increasing interest in the
association between metabolic syndrome
and depression and whether causal rela-
tionships are involved. The proposed link
is consistent with reports that depression
is associated with development of diabe-
tes and with poor glycemic control in es-
tablished diabetes (5). For instance,
Bjo¨rntorp (6) has hypothesized that psy-
chological problems are associated with
metabolic disorders via visceral fat accu-
mulation. The postulated role of the hy-
pothalamic-pituitary-adrenal (HPA) axis
in the pathogenesis of central adiposity
and metabolic syndrome has led to the
conceptualization of the metabolic syn-
drome as a neuroendocrine disorder (7).
To investigate the link between met-
abolic syndrome and depression, several
studies have been conducted with results
generally supporting an association of
metabolic syndrome with depression.
However, the groups studied were not
representative samples from the general
population with metabolic syndrome, be-
ing either relatively young (8,9), men only
(10), premenopausal women only
(11,12), or a clinically targeted popula-
tion (13) (Table 1). Other important vari-
ations such as study design, psychological
measures used, and definition of meta-
bolic syndrome used have led to inconsis-
tent results.
To the best of our knowledge, this is
the first study to assess evidence from a
randomized sample of a heterogeneous
population with a high prevalence of
metabolic syndrome (4) to determine
whether depression has an important as-
sociation with metabolic syndrome.
RESEARCH DESIGN AND
METHODS— Three cross-sectional
surveys of cardiovascular disease risk fac-
tors and related health behavior were car-
ried out in southeastern Australia (14) to
obtain rural data for comparison with the
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existing urban data. The first survey was
conducted from August to October 2004
in Limestone Coast (LC, South Australia),
the second in February to March 2005 in
Corangamite Shire (CO, Victoria), and
the third in May to October 2006 in the
Wimmera region (WI, Victoria). These re-
gions are predominantly rural farming
areas.
Each survey used a stratified random
sample of the population aged 25–74
years drawn from the electoral roll. Strat-
ification was by sex and 10-year age-
groups, with the exception of the
combined 25- to 44-year age-group con-
sidered as one stratum. The original sam-
ples consisted of 1,120 individuals in LC,
1,000 in CO, and 1,500 in WI. After ex-
cluding individuals who had died or had
left the region, a total of 552 people in LC
(participation rate 51%), 415 people in
CO (42%), and 596 people in WI (53%)
participated in the study. The WI sample
included an additional 127 subjects (par-
ticipation rate 44%) from the age-group
75–84 years.
The survey methodology, as previ-
ously described (4), comprised self-
administered questionnaires, physical
measurements, and laboratory tests. A
comparison of the socioeconomic back-
ground with population statistics avail-
able indicated that the participants closely









Herva et al. (9) 5,698 Men and women 31 mean HSCL-25 ATP III No clear association between
metabolic syndrome and
psychological distress
Kinder et al. (8) 6,189 Men and women 17–39 SCID ATP III Association between
metabolic syndrome and
depression in women only;
high blood pressure and
high triglycerides
associated with depression





Miller et al. (25) 100 Men and women 18–45 HAM-D; BDI * Evidence linking depressive
symptoms with
inflammatory processes as
part of the mechanism for
cardiovascular morbidity
and mortality
Raikkonen et al. (11)† 425 Women 42–50 (at study
entry)
BDI ATP III Depression, anxiety, tension,
and anger are associated
concurrently with and/or
predict the risk for
developing metabolic
syndrome






metabolic syndrome for all
criteria used




Skilton et al. (13) 1,598 Men and women 30–80 HADS-D ATP III; IDF Association between
metabolic syndrome and
depression in a cohort of
subjects at an increased risk
of cardiovascular disease
*Authors were not using any of the defined criteria of metabolic syndrome but were analyzing clusters of metabolic factors. †Longitudinal in design. BDI, Beck
Depression Inventory; CES-D, Centre for Epidemiological Studies–Depression Scale; HAM-D, Hamilton Rating Scale for Depression; HSCL, Hopkins Symptom
Checklist; SCID, Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders; WHO, World Health Organization.
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resembled the true populations of the ar-
eas surveyed (4).
Measures
The questionnaire, which included ques-
tions on health behavior, symptoms and
diseases, medical history, socioeconomic
background, and psychosocial factors, to-
gether with the invitation to attend the
health check, was sent by mail to all se-
lected participants. Health checks were
carried out in local health centers or other
survey sites by specially trained nurses.
In the health check, weight, height,
waist and hip circumference, systolic and
diastolic blood pressure, as well as fasting
lipids and glucose were ascertained, and
BMI was computed as described in more
detail elsewhere (4). The venous blood
samples were drawn after an overnight
fast of at least 10 h and analyzed at the
Flinders Medical Centre Clinical Trials
Laboratory, which is internationally ac-
credited for lipid measurement under the
Centres for Disease Control Lipid Stan-
dardization Program (Atlanta, GA) (4).
Metabolic syndrome definition
The following definitions of metabolic
syndrome were used. First, the most re-
cent NCEP ATP III (1) criteria require
three or more of the following: waist cir-
cumference 102 cm for men and 88
cm for women; fasting glucose 5.6
mmol/l or medication for high blood
glucose; systolic blood pressure 130
mmHg, diastolic blood pressure 85
mmHg, or antihypertensive medication;
triglycerides1.7 mmol/l; and HDL cho-
lesterol 1.03 mmol/l for men and
1.30 mmol/l for women.
Second, the International Diabetes
Federation (IDF) (2) criteria specify cen-
tral obesity with a waist circumference
94 cm for men and80 cm for women
of Europid origin, plus two or more of the
following: fasting plasma glucose 5.6
mmol/l or previously diagnosed type 2 di-
abetes; systolic blood pressure 130
mmHg, diastolic blood pressure 85
mmHg, antihypertensive medication;
plasma triglycerides 1.7 mmol/l; and
plasma HDL cholesterol 1.03 mmol/l
for men and 1.29 mmol/l for women.
Psychological measures
Depression and anxiety were measured
by the Hospital Anxiety and Depression
Scale (HADS) (15). The instrument con-
sists of seven items for anxiety (HADS-A)
and seven for depression (HADS-D), re-
ported by respondents over the last week.
Responses are scored on items from 0 to
3: separate summed scores for anxiety
and depression range from 0 to 21, where
normal is 0–7, mild is 8–10, moderate is
11–14, and severe is 15–21. In the
present study, we defined anxiety and de-
pression as having a score in the mild to
severe range (8).
Psychological distress was assessed
by the Kessler 10 measure (K10) (16), a
10-item measure of the anxiety and de-
pression symptoms experienced in the
most recent 4-week period. Responses are
recorded on a five-point scale, and the
score is the sum of the responses. Total
scores are categorized into two levels of
psychological distress: low (10–15) and
moderate– high (16 –50). The internal
consistency coefficients for the HADS-A,
HADS-D, and K10 in this study were 
0.82, 0.79, and 0.87, respectively.
Ethics approval for this study was
obtained from the Flinders University
Clinical Research Ethics Committee. In-
formed consent in writing was obtained
from participants when they attended the
health check component of the survey.
Statistical analysis
Statistical analyses were undertaken using
SPSS version 14.0. Internal consistency
was determined by using Cronbach’s .
Pearson correlation coefficients were used
to assess the intercorrelations between de-
pression, anxiety, and psychological
distress. Pearson 2 test was used to test
the associations of depression, anxiety,
and psychological distress with the pres-
ence of metabolic syndrome. Indepen-
dent t tests were used to compare mean
age and alcohol consumption for patients
with metabolic syndrome and for healthy
subjects. Multivariate analysis of covari-
ance was used to test differences between
individuals with the metabolic syndrome
and individuals without the metabolic
syndrome for psychological distress,
anxiety, and depression. ANCOVA was
used to examine the association between
depression and the five components of
metabolic syndrome simultaneously.
Analyses were adjusted for age, sex,
smoking status, alcohol intake, physical
activity, marital status, and education.
Nonsignificant covariates were not in-
cluded in the final models.
RESULTS— For 1,345 men and
women aged 25–84 years, information
was available for the metabolic syndrome,
HADS-D, HADS-A, K10, smoking status,
alcohol intake, and physical activity (Ta-
ble 2). A total of 409 (30.4%) participants
met the NCEP ATPIII criteria (1) for met-
abolic syndrome. A total of 90 partici-
pants (6.7%) had diabetes (based on self-
reported diabetes or fasting glucose7.0
mmol/l): 71 (5.3%) with and 19 (1.4%)
without the metabolic syndrome.
The characteristics of the 409 partic-
ipants with and 936 without the meta-
bolic syndrome are presented in Table 2,
which also shows the characteristics of
the 338 subjects without diabetes who
had the metabolic syndrome.
When comparing all 409 metabolic
syndrome participants with those with-
out the metabolic syndrome, no sex-
based prevalence differences were found.
Participants with metabolic syndrome
were older (mean 60.5 vs. 55.0 years,
P  0.001). The correlations between
depression (HADS-D) and anxiety
(HADS-A), depression and psychological
distress (K-10), and anxiety and psycho-
logical distress were 0.59 (95% CI
0.56–0.63), 0.66 (0.63–0.69), and 0.72
(0.69–0.74), respectively, and were all
significant (P 0.001). Participants with
the metabolic syndrome were more likely
to have moderate to severe depression
(10 vs. 6.9%, P  0.069); but the two
groups were not significantly different in
psychological distress (30.1 vs. 25.7%,
P 0.115) or anxiety (9.8 vs. 10.4%, P
0.820).
Multivariate analysis showed that
participants with metabolic syndrome by
NCEP ATP III criteria (1) had higher
scores for depression compared with in-
dividuals without the metabolic syn-
drome (mean scores 3.41 vs. 2.95, P 
0.013 [Table 3]) after adjusting for sex,
smoking status, alcohol intake, and phys-
ical activity.
When each of the components of the
metabolic syndrome was considered for
all participants, both the HDL cholesterol
and waist circumference components
were independently associated with de-
pression (Table 3). Participants with
lower HDL cholesterol had higher scores
for depression compared with individuals
with higher HDL cholesterol (mean
scores 3.75 vs. 2.93, P  0.003). Partici-
pants with a larger waist circumference
had higher scores for depression than in-
dividuals with smaller waist circumfer-
ence (mean scores 3.38 vs. 2.86, P 
0.002).
The 338 participants with the meta-
bolic syndrome but without diabetes
were similarly more likely to have moder-
ate to severe depression (10.1 vs. 6.9%,
Depression and the metabolic syndrome
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P  0.086 [Table 2]). Again, no signifi-
cant differences between groups were
found in psychological distress (30.5 vs.
25.7%, P  0.108) or anxiety (9.2 vs.
10.4%, P  0.604). Association of low
HDL cholesterol (mean depression scores
3.68 vs. 2.92, P 0.004) and large waist
circumference (mean depression scores
3.36 vs. 2.86, P 0.003) with depression
were also found (Table 3).
Similar results were obtained when
using IDF criteria (2). Participants (n 
409) with the metabolic syndrome had
higher scores for depression than individ-
uals without the metabolic syndrome
(mean scores 3.30 vs. 2.95, P  0.035,
data not shown) after controlling for co-
variates. In the group of 338 participants
with the metabolic syndrome but without
diabetes, we obtained the same associa-
tion when using the IDF criteria (mean
scores 3.27 vs. 2.95, P  0.070, data not
shown). Metabolic syndrome was associ-
ated with depression, anxiety, and psy-
chological distress in the 409 participants
with metabolic syndrome (P  0.009) as
well as the 338 participants without dia-
betes (P  0.032) when combined in
multivariate analyses and adjusted for the
same covariates.
CONCLUSIONS— In the present
study, we have demonstrated an associa-
tion between metabolic syndrome and
depression. Although the association is
modest, it is important because of the in-
creasing prevalence of metabolic syn-
drome and the effect that depression can
have on the ability of patients to success-
Table 2—Sample characteristics of participants aged 25–84 years
n (%) n (%) P† n (%) P†
A B A vs. B C A vs. C
Overall metabolic syndrome No Yes (diabetes included) Yes (diabetes excluded)
n 936 (100) 409 (100) 338 (100)
Sex 0.306 0.338
Men 446 (47.6) 208 (50.9) 172 (50.9)
Women 490 (52.4) 201 (49.1) 166 (49.1)
Diabetes (self-reported or fasting glucose
7.0 mmol/l) 19 (2.0) 71 (17.4) 0.001 NA NA
Age (years) 55.0  13.1 60.5  10.8 0.001 59.8  10.9 0.001
Smoking 0.250 0.488
Current 132 (14.1) 49 (12.0) 34 (10.1)
Ex-smoker 303 (32.4) 150 (36.7) 111 (32.8)
Nonsmoker 501 (53.5) 210 (51.3) 193 (57.1)
Alcohol (g/week) 7.4  11.6 6.6  10.6 0.196 6.9  10.9 0.442
Daily physical activity (30 min) 767 (81.9) 314 (76.8) 0.034 261 (77.2) 0.071
Depression 65 (6.9) 41 (10.0) 0.069 34 (10.1) 0.086
Anxiety 97 (10.4) 40 (9.8) 0.820 31 (9.2) 0.604
Psychological distress 241 (25.7) 123 (30.1) 0.115 103 (30.5) 0.108
Metabolic syndrome components*
Elevated fasting glucose 112 (12.1) 247 (60.1) 0.001 176 (52.7) 0.001
Hypertension 441 (47.1) 374 (91.4) 0.001 306 (40.5) 0.001
Elevated triglycerides 129 (13.9) 281 (71.1) 0.001 239 (72.2) 0.001
Low HDL cholesterol 67 (7.2) 194 (47.8) 0.001 158 (46.7) 0.001
Central obesity 226 (24.3) 351 (86.2) 0.001 288 (85.5) 0.001
Data are n (%) or means SD. *Cutoffs are for NCEP ATP III criteria as defined in RESEARCH DESIGN AND METHODS. †P values were obtained by 2 or independent t
test, as appropriate. A: Participants without metabolic syndrome. B: Participants with metabolic syndrome including those with type 2 diabetes. C: Participants with
the metabolic syndrome, excluding those with type 2 diabetes. NA, not available.
Table 3—Results of ANOVA for mean HADS-Depression scores by metabolic syndrome (NCEP ATP III) and its components for participants
aged 25–84 years
Including participants with both metabolic
syndrome and diabetes (n  1,345)
Excluding participants with both metabolic
syndrome and diabetes (n  1,274)
Mean (95% CI) Mean (95% CI) P Mean (95% CI) Mean (95% CI) P
Overall metabolic syndrome Yes No Yes No
3.41 (3.12–3.70) 2.95 (2.76–3.13) 0.013 3.37 (3.06–3.68) 2.95 (2.76–3.13) 0.030
Components Abnormal Normal Abnormal Normal
Fasting glucose 3.14 (2.84–3.44) 3.06 (2.88–3.24) 0.198 3.03 (2.71–3.35) 3.06 (2.88–3.24) 0.190
Blood pressure 3.18 (2.98–3.38) 2.94 (2.70–3.19) 0.395 3.14 (2.93–3.35) 2.95 (2.70–3.19) 0.414
Triglycerides 3.17 (2.89–3.45) 3.04 (2.85–3.22) 0.281 3.13 (2.84–3.41) 3.02 (2.83–3.21) 0.238
HDL cholesterol 3.75 (3.37–4.13) 2.93 (2.76–3.10) 0.003 3.68 (3.28–4.09) 2.92 (2.75–3.10) 0.004
Waist circumference 3.38 (3.14–3.63) 2.86 (2.66–3.06) 0.002 3.36 (3.10–3.62) 2.86 (2.66–3.06) 0.003
Dunbar and Associates
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fully make lifestyle changes and comply
with medication required for hyperten-
sion and dyslipidemia.
The association is demonstrated here
in a general population to our knowledge
for the first time, whereas earlier studies
(Table 1) used subgroups of populations
(8–13,17). This association between met-
abolic syndrome and depression was
present regardless of diabetes status. This
distinction is important because many in-
dividuals with metabolic syndrome have
diabetes, which itself is known to be as-
sociated with depression (5).
Metabolic syndrome has been defined
in several ways that involve quantitative
anthropometric, clinical, and laboratory
measurements (1,2). For the primary as-
sessment, we chose NCEP ATP III (1) cri-
teria, since these criteria were used in
most of the previously reported studies
(8,9,11–13,17). In addition, we used the
more recently described IDF criteria (2),
with a lower cutoff point for waist circum-
ference, and showed that the association
was consistent across both definitions.
Of the components of metabolic syn-
drome, increased waist circumference
was associated with depression, as re-
ported in another study using a restricted
population sample (9). This association is
present regardless of the diabetes status
and remained even when adjusted for
significant covariates. We also found a
significant independent relationship be-
tween low HDL cholesterol level and de-
pression (Table 3). This finding appears
to be consistent with other recent re-
search (17), but the underlying mecha-
nism remains unknown.
There has been little consistency in
the psychological tests used in previous
studies to measure depression (Table 1).
Assessment varies from individual inter-
view instruments (e.g., The Structured
Clinical Interview for DSM Disorders or
the Hopkins Symptom Checklist) to self-
reported epidemiological measures (e.g.,
Centre for Epidemiological Studies–
Depression Scale) (Table 1). Most mea-
sures include somatic components of
depression, and the length of recall ranges
from present symptoms to past months.
Symptoms are recorded in either intensity
or presence. In this study, we used the
HADS, which has been designed for and
validated in medical patients. It measures
the presence of cognitive and affective
components of depression and, unlike
other instruments, excludes many of the
somatic symptoms of depression (fatigue,
loss of appetite and weight, sleep distur-
bance, psychomotor changes) that may
overlap with physical problems. In addi-
tion, the length of recall is limited to the
past week. The HADS is widely used in
population health studies and screening
in primary care, although it has only been
used in one reported study (13) linking
metabolic syndrome and depression.
The pathophysiological basis for the
association between metabolic syndrome
and depression is likely to be complex
and to involve the inflammatory state that
has been described as a consequence of
central obesity (18). Bjo¨rntorp (7) postu-
lated that psychosocial factors, including
depression, can activate the HPA axis,
producing hypersecretion of corticotro-
phin-releasing hormone, adrenocortico-
tropic hormone, and cortisol. This
dysregulation of the HPA axis promotes
deposition of visceral adipose tissue (6),
which secretes inflammatory cytokines
such as interleukin (IL)-1 and IL-6 and
tumor necrosis factor (TNF)- (19,20).
Both IL-6 and TNF- have been impli-
cated in insulin resistance, which is con-
sidered to be the key factor in the
metabolic abnormalities (21) of the met-
abolic syndrome. The proinflammatory
response associated with depression may
also have a direct effect on dyslipidemia
(22). An alternative construct of the link
between metabolic syndrome and depres-
sion places development of central obe-
sity and activation of inflammatory
processes as the initiating step. Depres-
sion is seen as being a consequence of
this immune activation (23). In this
model, development of depression is
analogous to “sickness behavior,” which
can be associated with viral infection or
other causes of immune activation. Dys-
regulation of the HPA axis can occur via
cytokine-induced stimulation of the cen-
tral noradrenergic stress system (24).
The main limitation of our study is
the cross-sectional design, which does not
allow for the demonstration of the exis-
tence of HPA axis activation and an in-
flammatory state in participants with
central obesity. Establishment of this link
requires both longitudinal investigation
and further analysis of blood samples,
which would allow direct examination of
the link between depression, inflamma-
tory state, and metabolic syndrome. An-
other limitation of this study is the rural
population; the association still needs to
be demonstrated in urban groups as well
as those who have greater cultural and
socioeconomic diversity. While the char-
acteristics of participants in our study
closely resembled those of the local pop-
ulations surveyed (4), it is possible that
depressed individuals may have been less
likely to participate. If this is the case, the
present findings could over- or understate
the association.
In summary, our data show an asso-
ciation between the metabolic syndrome
and the cognitive and affective compo-
nents of depression in a general popula-
tion, where the prevalence of depression
in individuals with the metabolic syn-
drome is 50% higher. The importance of
our study lies in the heterogeneity of the
sample used. Contrasting other studies,
conclusions we have made are unlikely to
be attributed to idiosyncrasies of the sam-
ple. Based on the findings in this study,
awareness of depressive symptoms as part
of metabolic syndrome could be impor-
tant in clinical management as in other
chronic diseases. Acknowledgment of de-
pressive symptoms by the practitioner
and the patient should improve ability to
undertake lifestyle changes with adjust-
ment of physical activity and food intake,
as well as adherence to medications that
are likely to be compromised by depres-
sion. Identification and management of
depression should therefore precede or
accompany other measures in the man-
agement of metabolic syndrome. It is also
possible that treatment of metabolic syn-
drome with lifestyle changes will amelio-
rate depression through reduction of
visceral adiposity and inflammation. In-
tervention studies to address this hypoth-
esis could provide further insight into the
relationship between depression, central
obesity, and inflammation.
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